Press Releases Centessa Pharmaceuticals plc

Equities

CNTA

US1523091007

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
8.97 ^USD	-6.07%		-5.28%	+12.69%

04-24	Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge	MT
04-24	Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares	04-24	GL
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares	04-23	GL
Centessa Pharmaceuticals Announces Open IND for ORX750, Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024	04-23	AQ
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024	04-22	GL
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024	04-22	AQ
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023	03-28	GL
Centessa Pharmaceuticals : March Corporate Overview	03-05	PU
Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference	02-22	GL
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)	02-09	GL
Scion Life Sciences Launches with Oversubscribed $310 Million Fund to Create and Build Exceptional Biotech Companies	02-08	AQ
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences	01-22	GL
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences	01-22	AQ
Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference	12-13	GL
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia	12-11	AQ
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia	12-10	AQ
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia	12-10	GL
Hemophilia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 \| Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics	12-08	AQ
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023	11-13	GL
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting	11-02	GL
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors	31/10/23	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Centessa Pharmaceuticals plc

Equities

CNTA

US1523091007

Press Releases

Filters